menu
    • menu
    [{"orgOrder":0,"company":"Etana Biotechnologies","sponsor":"Yunfeng Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDONESIA","productType":"Antibody, Unconjugated","year":"2023","type":"Financing","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Etana Biotechnologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Etana Biotechnologies \/ Yunfeng Capital","highestDevelopmentStatusID":"15","companyTruncated":"Etana Biotechnologies \/ Yunfeng Capital"},{"orgOrder":0,"company":"Etana Biotechnologies","sponsor":"Innovent Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Etana Biotechnologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Etana Biotechnologies \/ Etana Biotechnologies","highestDevelopmentStatusID":"15","companyTruncated":"Etana Biotechnologies \/ Etana Biotechnologies"},{"orgOrder":0,"company":"Etana Biotechnologies","sponsor":"Innovent Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Approved FDF","graph3":"Etana Biotechnologies","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Etana Biotechnologies \/ Etana Biotechnologies","highestDevelopmentStatusID":"15","companyTruncated":"Etana Biotechnologies \/ Etana Biotechnologies"}]

    Find Clinical Drug Pipeline Developments & Deals by Etana Biotechnologies

    Menu

    Etana Biotechnologies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Etana Biotechnologies

                            Indonesia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Etana Biotechnologies

                            Indonesia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Yunfeng Capital

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Etana Has Secured Financing From Deg, East Ventures And Other Global Investors

                            Details : The financing will be used for further strengthening the company’s pipeline and portfolio especially in Oncology area. Etana will produce Bevagen (bevacizumab biosimilar), a recombinant humanized anti-VEGF monoclonal antibody drug for cancer patients i...

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            March 20, 2023

                            Lead Product(s) : Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Yunfeng Capital

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Etana Biotechnologies

                            Indonesia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Etana Biotechnologies

                            Indonesia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bevacizumab,Fluoropyrimidine,Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Innovent Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Innovent and Etana Jointly Announce the Approval of Bevagen® (Bevacizumab Biosimilar) by the Indonesian Food ...

                            Details : Bevagen®(Bevacizumab) is biosimilar of the recombinant humanized anti-VEGF monoclonal antibody bevacizumab. Vascular endothelial growth factor (VEGF) is a critical factor in promoting angiogenesis, and is highly expressed by the endothelial cells in mos...

                            Product Name : Bevagen

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            June 14, 2022

                            Lead Product(s) : Bevacizumab,Fluoropyrimidine,Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Innovent Biologics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Etana Biotechnologies

                            Indonesia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Etana Biotechnologies

                            Indonesia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Innovent Biologics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Innovent Announces an Out-license Agreement with PT Etana Biotechnologies Indonesia to Launch BYVASDA® in Ind...

                            Details : Etana is committed to launch BYVASDA® in the local market. In return, Innovent will receive milestones for development and commercialization as well as double-digit royalties on net sales.

                            Product Name : Byvasda

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            January 19, 2021

                            Lead Product(s) : Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Innovent Biologics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth